الفهرس 
INRRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Allogeneic hematopoietic stem cell transplantation refers to transfusion into the recipient stem cells collected from either the peripheral blood, cord blood, or bone marrow of the donors.
Transplantation of HSC in general usually prescribed for both benign and malignant hematological conditions and for both adults and children.
Allogeneic transplantation represents the most efficient consolidation treatment for most cases of malignant diseases. Some progression was made in the practice of transplantation but still, GvHD, relapse, and infection are the main obstacles. The cumulative incidence of cGvHD by 1 year after transplant ranged from 30-70 %. GvHD is the most common non-relapse mortality (NRM), and accounts of about 10–25 % of all transplanted patients.
Advanced chemotherapy protocols, potent antimicrobial drugs in addition to better supportive care have resulted in a marked reduction in the early morbidity and mortality in HSCT.
There are many factors which enhance the incidence of GvHD such as old age for recipient or donor, sex mismatch especially transplant of a male patient from the female recipient, peripheral blood source of stem cells, ABO and HLA incompatibility, GvHD prophylaxis, the status of the disease at the time of transplantation, comorbidities, and type of induction chemotherapy prior to transplantation.
CGvHD is defined by the National Institutes of Health (NIH) Consensus depending on clinical manifestations, changing the classical
and rather arbitrary chronological “beyond Day 100” definition. There are two types of cGvHD: Classic and overlap. The severity of cGvHD also assessed by the NIH global severity of cGvHD.
There are major roles for both T-cells and B-cells and their secreted cytokines in the pathogenesis of cGvHD.
Biomarkers included in this prospective study were used to predict their roles of early detection of early cGvHD. The panel of biomarkers used included (IFN-γ, TNF-α, IL-15, and IL-10). These biomarkers are either anti-inflammatory or pro-inflammatory.
Samples collected from 20 adult patients and sera extracted to practice the test to evaluate the concentration for each case, it worth mentioning that samples collected at days (30-90-180).